Literature DB >> 6628924

Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis.

K Nilsell, B Angelin, B Leijd, K Einarsson.   

Abstract

The effects of ursodeoxycholic acid on biliary lipid secretion and bile acid kinetics were determined in 12 men. For comparison, eight of the subjects were also treated with chenodeoxycholic acid using a crossover study design. The daily dose of each bile acid was 15 mg/kg body wt; each treatment period lasted for 5-6 wk. Kinetics of cholic acid and chenodeoxycholic acid, hepatic secretion rates of biliary lipids, and lipid composition of concentrated fasting duodenal bile were determined before and at the end of each treatment period. The synthesis rates of cholic acid and chenodeoxycholic acid were increased by approximately 80% and 40%, respectively, during treatment with ursodeoxycholic acid. The fractional catabolic rates of the two bile acids were increased by approximately 50%, whereas the pool sizes remained unchanged. Under similar conditions, administration of chenodeoxycholic acid reduced the pool size as well as the synthesis rate of cholic acid by approximately 70%. Ursodeoxycholic acid reduced the hepatic secretion of cholesterol to a higher extent (approximately 50%) than did chenodeoxycholic acid (approximately 30%). The secretion rates of bile acids and phospholipids remained essentially unchanged during the two treatment periods. Fasting duodenal (gallbladder) bile was unsaturated with cholesterol during both regimens. It is concluded that the two bile acids exert different effects on bile acid metabolism. The enhanced conversion of cholesterol to bile acids observed during ursodeoxycholic acid treatment may at least partly explain why ursodeoxycholic acid can reduce the biliary output of cholesterol without suppressing hepatic cholesterol synthesis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628924

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  26 in total

1.  Disorder of bile acid metabolism in children with short bowel syndrome.

Authors:  N Ohkohchi; T Andoh; U Izumi; Y Igarashi; R Ohi
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

2.  The effectual level of ursodeoxycholic acid in therapy for non-advanced chronic cholestasis is fifty percent of total serum bile acids.

Authors:  T Higuchi; N Hishida; T Isomura; H Takeshima; H Hayashi
Journal:  Gastroenterol Jpn       Date:  1992-04

3.  Feedback regulation of bile-acid synthesis in the rat. Differing effects of taurocholate and tauroursocholate.

Authors:  S Shefer; L Nguyen; G Salen; A K Batta; D Brooker; F G Zaki; I Rani; G S Tint
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

4.  Hepatic biliary lipid secretion and gall bladder biliary lipid mass in gall stone patients: effect of ursodeoxycholic acid.

Authors:  A Lanzini; T C Northfield
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

5.  Influence of cholestasis on absorption of ursodeoxycholic acid.

Authors:  P Sauer; C Benz; G Rudolph; P Klöters-Plachky; W Stremmel; A Stiehl
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

6.  Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis.

Authors:  G Mazzella; P Parini; F Bazzoli; N Villanova; D Festi; R Aldini; A Roda; A Cipolla; C Polimeni; D Tonelli
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

7.  Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.

Authors:  S Okamoto; K Nakano; K Kosahara; M Kishinaka; H Oda; H Ichimiya; K Chijiiwa; S Kuroki
Journal:  J Gastroenterol       Date:  1994-02       Impact factor: 7.527

8.  Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.

Authors:  S Güldütuna; M Leuschner; N Wunderlich; A Nickel; S Bhatti; K Hübner; U Leuschner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  No effect of probenecid on the renal and biliary clearances of digoxin in man.

Authors:  A Hedman; B Angelin; A Arvidsson; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

10.  Ursodeoxycholic acid increases low-density lipoprotein binding, uptake and degradation in isolated hamster hepatocytes.

Authors:  B Bouscarel; H Fromm; S Ceryak; M M Cassidy
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.